Lead Product(s): CRS3123
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: National Institutes of Health
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding April 27, 2020
Under this grant from NIH, Crestone’s drug candidate CRS3123 will be tested for pharmacokinetic properties and efficacy in an established preclinical model of H. pylori infection of the stomach.